Form 8-K Revance Therapeutics, For: Nov 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Revance Therapeutics (RVNC) Tops Q3 EPS by 9c
November 12, 2014 4:19 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.60), $0.09 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $75 thousand, versus $158 thousand reported last year.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More